SermorelinvsThymulin

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-44). These 29 residues contain the full biological activity domain required for GHRH receptor activation — the remaining 15 amino acids of native GHRH are not necessary for receptor binding or signal transduction.

Sermorelin binds to the GHRH receptor on anterior pituitary somatotrophs, activating the Gs/adenylyl cyclase pathway to increase intracellular cAMP. This triggers PKA-mediated phosphorylation of CREB and stimulates both GH gene transcription and the release of pre-formed GH vesicles. Because sermorelin works through the body's own regulatory system, GH release occurs in a physiological pulsatile pattern governed by the interplay between GHRH stimulation and somatostatin inhibition — the hypothalamic-pituitary feedback loop remains intact.

This preservation of feedback regulation is sermorelin's primary safety advantage over exogenous GH administration. The pituitary gland can only release as much GH as it has synthesized, providing a natural ceiling effect that prevents supraphysiological GH levels. Somatostatin feedback still functions normally, ensuring appropriate pulse spacing. Additionally, because the pituitary itself is being stimulated rather than bypassed, sermorelin may help maintain or even restore pituitary somatotroph function over time. It was the first GHRH analogue to receive FDA approval (as Geref), specifically for evaluating pituitary GH reserve and treating pediatric GH deficiency, giving it one of the longest clinical track records among GH-stimulating peptides.

Thymulin (also known as facteur thymique sérique, FTS) is a nonapeptide (Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is unique among thymic hormones in requiring a zinc ion for biological activity. The zinc ion is coordinated by the asparagine (position 9), serine (position 4), and the N-terminal glutamic acid, creating a metallopeptide complex where the zinc is essential for the correct three-dimensional conformation needed for receptor binding. Without zinc, thymulin is biologically inactive — this zinc dependency has important implications for immune function in zinc-deficient individuals.

Thymulin is produced exclusively by thymic epithelial cells and is the only thymic hormone that is truly thymus-specific — its serum levels become undetectable after thymectomy (surgical thymus removal). It binds to high-affinity receptors on T-cell precursors (thymocytes) and mature T cells, promoting several key aspects of T-cell biology. It induces the expression of T-cell differentiation markers (CD2, CD3, CD4, CD8), driving immature thymocytes through the stages of T-cell maturation. It enhances the cytotoxic function of CD8+ T cells and the helper function of CD4+ T cells. It modulates the balance between T-helper and T-suppressor (regulatory) cell populations, promoting appropriate immune regulation.

Thymulin also modulates cytokine production — it promotes IL-2 secretion (essential for T-cell proliferation and the generation of effector T cells), enhances IFN-γ production (important for Th1 cellular immunity), and influences the balance of pro-inflammatory versus anti-inflammatory cytokines. Serum thymulin levels peak around puberty and decline progressively with age, becoming virtually undetectable by age 60 — mirroring the age-related involution of the thymus gland. This decline correlates closely with immunosenescence markers: reduced naive T-cell output, skewed CD4/CD8 ratios, impaired vaccine responses, and increased susceptibility to infections and cancer. Zinc supplementation alone can partially restore thymulin activity in zinc-deficient elderly individuals, highlighting the clinical importance of the zinc-thymulin interaction.